Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21155621 | 0.91 | DUT (0.32) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL1968456 | 0.81 | PDK2 (0.36) | — | |
| SCHEMBL24477527 | 0.79 | DUT (0.31) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL23067161 | 0.78 | DUT (0.31) | — | |
| SCHEMBL10223187 | 0.77 | DUT (0.31) | — | |
| SCHEMBL19832452 | 0.76 | CHRM2 (0.40) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL2875764 | 0.75 | ALDH1A1 (0.36) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL31294926 | 0.73 | DUT (0.33) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL18982352 | 0.73 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL17567264 | 0.73 | DUT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-11-26 | — | — | US | disclosed |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2021-11-25 | — | — | US | disclosed |
| EP-3858814-A1 | NITROXOLINE PRODRUG AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858814-A1 | NITROXOLINE PRODRUG AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-03-11 | — | — | US | disclosed |
| CN-111295372-B | Nitroxoline prodrugs and uses thereof | 江苏亚虹医药科技股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-111295372-A | Nitroxoline prodrugs and uses thereof | 江苏亚虹医药科技有限公司 | 2020-06-16 | — | — | CN | disclosed |
| WO-2020063824-A1 | NITROXOLINE PRODRUG AND USE THEREOF | 江苏亚虹医药科技有限公司 | 2020-04-02 | — | — | WO | disclosed |
| WO-2019136112-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | NOS1, NOS2, NNT | CHRNB2 4517/4885CHRNA4 4401/4885CHRM2 3548/4885 |
| US-20210070698-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | CHRNB2 2768/4885CHRNA4 3896/4885CHRM2 1793/4885 |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | CHRNB2 2768/4885CHRNA4 3896/4885CHRM2 1793/4885 |
| US-20210363165-A1 | NITROXOLINE PRODRUG AND USE THEREOF | NOS1, NOS2, NNT | CHRNB2 4517/4885CHRNA4 4401/4885CHRM2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.